Eversept Partners, LP Zentalis Pharmaceuticals, Inc. Transaction History

Eversept Partners, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Nov 08, 2023	SELL	$17.91 - $52.25 $1.11 Million - $3.23 Million	-61,845 Reduced 61.73%	38,342 $1.08 Million
Q2 2022 Aug 15, 2022	SELL	$17.91 - $52.25 $1.11 Million - $3.23 Million	-61,845 Reduced 61.73%	38,342 $1.08 Million
Q1 2022 Nov 08, 2023	BUY	$41.58 - $80.89 $4.17 Million - $8.1 Million	100,187 New	100,187 $4.62 Million
Q1 2022 May 16, 2022	BUY	$41.58 - $80.89 $1.54 Million - $2.99 Million	37,024 Added 58.62%	100,187 $4.62 Million
Q4 2021 Nov 08, 2023	BUY	$66.92 - $84.79 $4.23 Million - $5.36 Million	63,163 New	63,163 $5.31 Million
Q4 2021 Feb 14, 2022	BUY	$66.92 - $84.79 $4.23 Million - $5.36 Million	63,163 New	63,163 $5.31 Million

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $171M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Eversept Partners, LP with notifications on news.